BIOMAT Database Logo BIOMAT Database Logo

Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. 1996

E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Department of Infectious Diseases, Gaslini Children's Hospital, Genoa, Italy.

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D007898 Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African. Black Fever,Kala-Azar,Fever, Black,Kala Azar,Visceral Leishmaniasis
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Liposomal amphotericin B in the treatment of visceral leishmaniasis.
October 1991, The Journal of antimicrobial chemotherapy,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Liposomal amphotericin B for the treatment of visceral leishmaniasis.
October 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Visceral leishmaniasis following treatment with liposomal amphotericin B.
August 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
January 2006, Acta bio-medica : Atenei Parmensis,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Visceral leishmaniasis treated with liposomal amphotericin B.
January 1999, The Pediatric infectious disease journal,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B.
January 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
May 1991, Lancet (London, England),
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
April 2003, Fundamental & clinical pharmacology,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
October 2010, Transplant infectious disease : an official journal of the Transplantation Society,
E Castagnola, and R N Davidson, and P Fiore, and L Tasso, and G Rossi, and S Mangraviti, and L Di Martino, and S Scotti, and A Cascio, and R Pempinello, and L Gradoni, and R Giacchino
Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil.
October 1997, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
Copied contents to your clipboard!